logo-loader

Northland Capital Partners View on the City - Hemogenyx

no_picture_pai.jpg

HEMOGENYX PLC (LON:HEMO)

SECTOR – HEALTHCARE

RATING – CORP*

MARKET CAP – £10.9m

CURRENT PRICE – 2.9p#

ANALYSTS: LIAM GASCOIGNE-COHEN

 

Year-end Dec

2016A

2017A

2018E

2019E

2020E

 

Revenue (£m)

-

-

No forecasts provided

EBITDA (£m)

(0.5)

(2.3)

Pre-tax profit (£m)

(0.5)

(2.4)

EPS (p)

(0.00)

(0.01)

DPS (p)

-

-

Net Cash/(Debt) (£m)

(0.2)

 1.9

P/E (x)

-

-

Dividend yield (%)

-

-

EV/EBITDA (x)

-

-

 

SOURCE: Northland Capital Partners Limited estimates. #Priced at prior trading day close. *Northland Capital Partners Limited provides acts as Joint Broker to Hemogenyx plc and therefore this information should be viewed as a Marketing Communication.

 

Initiation of research: Disrupting current blood disease therapy (Note attached)

 

NORTHLAND VIEW

Hemogenyx is a biotechnology company quoted on the LSE Standard List. The Company is developing novel therapies for blood diseases which aim to offer a safer and more accessible patient pathway than current practice. Although the products are at the preclinical stage, the Company is already generating revenue through multiple collaborations with biopharmaceutical companies.

  • Modular platform technology: The Company is developing two products including an immunotherapy product (CDX Ab) for patient conditioning and a cell therapy (Hu-PHEC) for bone-marrow transplants.
  • Clear Milestones: With an established proof-of-principle for its CDX antibody platform, the Company is targeting the start of clinical trials in 2019.
  • Revenue-generating collaborations: With collaboration agreements signed across its pipeline, the Company is leveraging its platforms with large industry players to accelerate development and share the cost of development. This represents a strong validation of the Group’s products.

Although the Company has demonstrated strong progress across its pipeline, the share price remains below its IPO price of 3.5p/share. With multiple collaboration agreements and investment from industry we view the Company as undervalued.

 

 

COMPANY DESCRIPTION

Preclinical stage biotechnology company focused on the development of novel therapies for blood diseases.

 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharmaceuticals makes 'groundbreaking discovery' in its MATINS trial

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen speaks to Proactive London's Andrew Scott after updating on its phase I/II MATINS trial of Clevegen. He says it's been encouraging to discover that Clevegen can ‘down’ regulate a range of checkpoints that affect the...

28 minutes ago

5 min read